Sanofi, GSK secure $2.1bn from US in COVID-19 vaccine deal
03-08-2020
China approves three Gilead remdesivir patents for COVID-19 treatment
27-02-2020
Kira Yan / Shutterstock.com
US biotechnology company Novavax has signed a deal with Takeda Pharmaceuticals to develop, manufacture and market a COVID-19 vaccine in Japan, it was announced on Friday, August 7.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Novavax, Takeda, COVID-19, vaccine, Japan, NVX‑CoV2373, biotechnology, government, health, regulatory, market
